Incyte Corporation (INCY) Reports 2014 First-Quarter Financial Results And Updates Shareholders On Key Clinical Programs
5/1/2014 2:54:02 PM
Incyte Corporation (Nasdaq: INCY) today reported 2014 first-quarter financial results, including revenue from Jakafi® (ruxolitinib), which is approved by the U.S. Food & Drug Administration (FDA) for the treatment of patients with intermediate or high-risk myelofibrosis (MF).
Help employers find you! Check out all the jobs and post your resume.
comments powered by